A Web-Based Mental Health Intervention to Improve Social and Occupational Functioning in Adults With Type 2 Diabetes (The Springboard Trial): 12-Month Outcomes of a Randomized Controlled Trial.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 17 10 2019
accepted: 22 06 2020
revised: 26 02 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 16 3 2021
Statut: epublish

Résumé

People with type 2 diabetes mellitus (T2DM) often experience mental health symptoms that exacerbate illness and increase mortality risk. Access to psychological support is low in people with T2DM. Detection of depression is variable in primary care and can be further hampered by mental health stigma. Electronic mental health (eMH) programs may provide an accessible, private, nonstigmatizing mental health solution for this group. This study aims to evaluate the efficacy over 12 months of follow-up of an eMH program (myCompass) for improving social and occupational functioning in a community sample of people with T2DM and self-reported mild-to-moderate depressive symptoms. myCompass is a fully automated and self-guided web-based public health program for people with depression or anxiety. The effects of myCompass on depressive symptoms, diabetes-related distress, anxiety symptoms, and self-care behavior were also examined. Adults with T2DM and mild-to-moderate depressive symptoms (N=780) were recruited via online advertisements, community organizations, and general practices. Screening, consent, and self-report questionnaires were administered online. Eligible participants were randomized to receive either myCompass (n=391) or an attention control generic health literacy program (Healthy Lifestyles; n=379) for 8 weeks. At baseline and at 3, 6, and 12 months postintervention, participants completed the Work and Social Adjustment Scale, the Patient Health Questionnaire-9 item, the Diabetes Distress Scale, the Generalized Anxiety Disorder Questionnaire-7 item, and items from the Self-Management Profile for Type 2 Diabetes. Glycosylated hemoglobin measurements were obtained at baseline and 6 and 12 months postintervention. A total of 38.9% (304/780) of the trial participants completed all postintervention assessments. myCompass users logged in on an average of 6 times and completed an average of 0.29 modules. Healthy Lifestyles users logged in on an average of 4 times and completed an average of 1.37 modules. At baseline, the mean scores on several outcome measures, including the primary outcome of work and social functioning, were close to the normal range, despite a varied and extensive recruitment process. Intention-to-treat analyses revealed slightly greater improvement at 12 months in work and social functioning for the Healthy Lifestyles group relative to the myCompass group. All participants reported equivalent improvements in depression anxiety, diabetes distress, diabetes self-management, and glycemic control across the trial. The Healthy Lifestyles group reported higher ratings of social and occupational functioning than the myCompass group, but no differences were observed for any secondary outcome. Although these findings should be interpreted in light of the near-floor symptom scores at baseline, the trial yields important insights into how people with T2DM might be engaged in eMH programs and the challenges of focusing specifically on mental health. Several avenues emerge for continued investigation into how best to deal with the growing mental health burden in adults with T2DM. Australian New Zealand Clinical Trials Registry Number (ACTRN) 12615000931572; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368109&isReview=true.

Sections du résumé

BACKGROUND
People with type 2 diabetes mellitus (T2DM) often experience mental health symptoms that exacerbate illness and increase mortality risk. Access to psychological support is low in people with T2DM. Detection of depression is variable in primary care and can be further hampered by mental health stigma. Electronic mental health (eMH) programs may provide an accessible, private, nonstigmatizing mental health solution for this group.
OBJECTIVE
This study aims to evaluate the efficacy over 12 months of follow-up of an eMH program (myCompass) for improving social and occupational functioning in a community sample of people with T2DM and self-reported mild-to-moderate depressive symptoms. myCompass is a fully automated and self-guided web-based public health program for people with depression or anxiety. The effects of myCompass on depressive symptoms, diabetes-related distress, anxiety symptoms, and self-care behavior were also examined.
METHODS
Adults with T2DM and mild-to-moderate depressive symptoms (N=780) were recruited via online advertisements, community organizations, and general practices. Screening, consent, and self-report questionnaires were administered online. Eligible participants were randomized to receive either myCompass (n=391) or an attention control generic health literacy program (Healthy Lifestyles; n=379) for 8 weeks. At baseline and at 3, 6, and 12 months postintervention, participants completed the Work and Social Adjustment Scale, the Patient Health Questionnaire-9 item, the Diabetes Distress Scale, the Generalized Anxiety Disorder Questionnaire-7 item, and items from the Self-Management Profile for Type 2 Diabetes. Glycosylated hemoglobin measurements were obtained at baseline and 6 and 12 months postintervention.
RESULTS
A total of 38.9% (304/780) of the trial participants completed all postintervention assessments. myCompass users logged in on an average of 6 times and completed an average of 0.29 modules. Healthy Lifestyles users logged in on an average of 4 times and completed an average of 1.37 modules. At baseline, the mean scores on several outcome measures, including the primary outcome of work and social functioning, were close to the normal range, despite a varied and extensive recruitment process. Intention-to-treat analyses revealed slightly greater improvement at 12 months in work and social functioning for the Healthy Lifestyles group relative to the myCompass group. All participants reported equivalent improvements in depression anxiety, diabetes distress, diabetes self-management, and glycemic control across the trial.
CONCLUSIONS
The Healthy Lifestyles group reported higher ratings of social and occupational functioning than the myCompass group, but no differences were observed for any secondary outcome. Although these findings should be interpreted in light of the near-floor symptom scores at baseline, the trial yields important insights into how people with T2DM might be engaged in eMH programs and the challenges of focusing specifically on mental health. Several avenues emerge for continued investigation into how best to deal with the growing mental health burden in adults with T2DM.
TRIAL REGISTRATION
Australian New Zealand Clinical Trials Registry Number (ACTRN) 12615000931572; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368109&isReview=true.

Identifiants

pubmed: 33258790
pii: v22i12e16729
doi: 10.2196/16729
pmc: PMC7738252
doi:

Banques de données

ANZCTR
['ACTRN12615000931572']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e16729

Informations de copyright

©Peter Andrew Baldwin, Samineh Sanatkar, Janine Clarke, Susan Fletcher, Jane Gunn, Kay Wilhelm, Lesley Campbell, Nicholas Zwar, Mark Harris, Helen Lapsley, Dusan Hadzi-Pavlovic, Helen Christensen, Judy Proudfoot. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 01.12.2020.

Références

JMIR Res Protoc. 2017 Aug 03;6(8):e145
pubmed: 28778848
J Nephropharmacol. 2015 Sep 09;5(2):110-115
pubmed: 28197516
JAMA Psychiatry. 2017 Apr 1;74(4):351-359
pubmed: 28241179
BMJ Open. 2018 Aug 17;8(8):e020677
pubmed: 30121593
BMC Psychiatry. 2013 Nov 18;13:312
pubmed: 24237617
PLoS One. 2010 Oct 13;5(10):e13196
pubmed: 20967242
Health Aff (Millwood). 2009 May-Jun;28(3):w490-501
pubmed: 19366722
Diabetes Care. 2005 Mar;28(3):626-31
pubmed: 15735199
Diabetes Care. 2014 Apr;37(4):970-8
pubmed: 24198303
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
BMC Fam Pract. 2018 Dec 23;19(1):202
pubmed: 30579329
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Psychosom Res. 2017 Apr;95:44-54
pubmed: 28314548
Int J Epidemiol. 2008 Oct;37(5):941-7
pubmed: 17881411
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
pubmed: 23264422
J Affect Disord. 2012 Oct;142 Suppl:S8-21
pubmed: 23062861
J Clin Psychol. 2001 Apr;57(4):457-78
pubmed: 11255202
JMIR Ment Health. 2016 May 31;3(2):e23
pubmed: 27245948
Health Qual Life Outcomes. 2012 Oct 05;10:125
pubmed: 23039868
J Med Internet Res. 2019 May 21;21(5):e12246
pubmed: 31115345
BMC Psychiatry. 2010 Mar 21;10:25
pubmed: 20302678
Personal Ment Health. 2017 Nov;11(4):215-228
pubmed: 28681505
Clin Psychol Rev. 2011 Dec;31(8):1239-46
pubmed: 21963669
Health Expect. 2018 Jun;21(3):668-677
pubmed: 29319923
J Med Internet Res. 2017 May 15;19(5):e157
pubmed: 28506956
Lancet Neurol. 2006 Jan;5(1):64-74
pubmed: 16361024
Diabetes Care. 2010 Jan;33(1):23-8
pubmed: 19837786
J Med Internet Res. 2005 Mar 31;7(1):e11
pubmed: 15829473
Diabetes Care. 2011 Feb;34(2):320-5
pubmed: 21216855
J Med Internet Res. 2019 May 24;21(5):e12793
pubmed: 31127718
Diabet Med. 2014 Jul;31(7):764-72
pubmed: 24606397
Clin Psychol Rev. 2014 Mar;34(2):141-57
pubmed: 24508685
Mayo Clin Proc. 2005 Dec;80(12):1558-67
pubmed: 16342648
Sci Rep. 2018 May 18;8(1):7846
pubmed: 29777153
BMC Health Serv Res. 2010 Aug 12;10:235
pubmed: 20704720
Ann Fam Med. 2010 Jul-Aug;8(4):348-53
pubmed: 20644190
Drugs. 2015 Apr;75(6):577-87
pubmed: 25851098
Acta Psychiatr Scand Suppl. 2004;(420):47-54
pubmed: 15128387

Auteurs

Peter Andrew Baldwin (PA)

Black Dog Institute, Randwick, Australia.

Samineh Sanatkar (S)

Black Dog Institute, Randwick, Australia.

Janine Clarke (J)

Black Dog Institute, Randwick, Australia.

Susan Fletcher (S)

University of Melbourne, Melbourne, Australia.

Jane Gunn (J)

University of Melbourne, Melbourne, Australia.

Kay Wilhelm (K)

UNSW Sydney, Randwick, Australia.

Lesley Campbell (L)

UNSW Sydney, Randwick, Australia.

Nicholas Zwar (N)

UNSW Sydney, Randwick, Australia.

Mark Harris (M)

UNSW Sydney, Randwick, Australia.

Helen Lapsley (H)

UNSW Sydney, Randwick, Australia.

Dusan Hadzi-Pavlovic (D)

Black Dog Institute, Randwick, Australia.

Helen Christensen (H)

Black Dog Institute, Randwick, Australia.

Judy Proudfoot (J)

Black Dog Institute, Randwick, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH